Related Experiment Video
Updated: Jul 7, 2026
09:28
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
Published on: May 18, 2020
Overcoming further challenges in the pharma/biotech industry: 2007 update
Drug News & Perspectives
|February 28, 2008
Summary
Pharmaceutical companies are facing patent expirations and declining innovation. To address this, they are actively pursuing acquisitions, licensing, and collaborations to strengthen their drug development pipelines.
Area of Science:
- Pharmaceutical industry
- Drug development
- Biotechnology
Background:
- Declining innovation rates in the pharmaceutical sector.
- Impending patent expirations for major drug products.
- Increased pressure on research and development (R&D) operations.
Purpose of the Study:
- To analyze the strategic responses of pharmaceutical companies to industry challenges.
- To investigate methods for bolstering drug pipelines amidst R&D restructuring.
Main Methods:
- Review of industry trends and corporate strategies.
- Analysis of acquisition and licensing activities.
- Examination of research collaboration models.
Main Results:
- Companies are increasingly engaging in mergers and acquisitions (M&A).
- Licensing agreements are being utilized to access external innovation.
- Strategic research partnerships are forming to share risk and resources.
Conclusions:
- Pharmaceutical firms are adopting aggressive external strategies to compensate for internal R&D limitations.
- Diversification of drug pipelines through M&A, licensing, and collaborations is a key survival tactic.
- These strategies aim to mitigate risks associated with patent cliffs and innovation shortfalls.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...